New in silico and conventional in vitro approaches to advance HIV drug discovery and design

Expert Opinion on Drug Discovery

Volumn 8, Issue 1, 2013, Pages 83-92

  Maga, Giovanni ^a   Veljkovic, Nevena ^b   Crespan, Emmanuele ^a   Spadari, Silvio ^a   Prljic, Jelena ^b   Perovic, Vladimir ^b   Glisic, Sanja ^b   Veljkovic, Veljko ^b  

^a CNR   (Italy)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Enzyme kinetics; HIV drugs; Long range intermolecular interaction; Virtual screening

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FLAVANOID; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ANTIVIRAL ACTIVITY; BINDING SITE; CATALYSIS; CHEMICAL INTERACTION; COMPUTER MODEL; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME KINETICS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; ISOTHERMAL TITRATION CALORIMETRY; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; REVIEW; STATIC ELECTRICITY; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; THREE DIMENSIONAL IMAGING;

ANIMALS; ANTI-HIV AGENTS; COMPUTER SIMULATION; DRUG DESIGN; DRUG DISCOVERY; HIV INFECTIONS; HUMANS;

EID: 84871588015     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2013.741118     Document Type: Review

References (81)

1. Terstappen GC, Reggiani A. In silico research in drug discovery. Trends Pharmacol Sci 2001;22:23-6
2. Brass AL, Dykxhoorn DM, Benita Y, et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science 2008;319:921-6
3. Dias R, de Azevedo WF Jr. Molecular docking algorithms. Curr Drug Targets 2008;9:1040-7
4. Dror O, Shulman-Peleg A, Nussinov R, Wolfson HJ. Predicting molecular interactions in silico: I. A guide to pharmacophore identification and its applications to drug design. Curr Med Chem 2004;11:71-90
5. Wolber G, Langer T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model 2005;45:160-9
6. Steindl TM, Schuster D, Wolber G, et al. High-throughput structure-based pharmacophore modelling as a basis for successful parallel virtual screening. J Comput Aided Mol Des 2006;20:703-15
7. Kirchmair J, Ristic S, Eder K, et al. Fast and efficient in silico 3D screening: toward maximum computational efficiency of pharmacophore-based and shape-based approaches. J Chem Inf Model 2007;47:2182-96
8. Wolber G, Seidel T, Bendix F, Langer T. Molecule-pharmacophore superpositioning and pattern matching in computational drug design. Drug Discov Today 2008;13:23-9
9. Tintori C, Corradi V, Magnani M, et al. Targets looking for drugs: a multistep computational protocol for the development of structure-based pharmacophores and their applications for hit discovery. J Chem Inf Model 2008;48:2166-79
10. Gedeck P, Lewis R. Exploiting QSAR models in lead optimization. Curr Opin Drug Discov Devel 2008;11:569-75
11. Kirchmair J, Distinto S, Schuster D, et al. Enhancing drug discovery through in silico screening: strategies to increase true positives retrieval rates. Curr Med Chem 2008;15:2040-53
12. Kirchmair J, Markt P, Distinto S, et al. Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection-what can we learn from earlier mistakes? J Comput Aided Mol Des 2008;22:213-28
13. Schnur DM. Recent trends in library design: 'rational design' revisited. Curr Opin Drug Discov Devel 2008;11:375-80
14. Klepeis JL, Lindorff-Larsen K, Dror RO, Shaw DE. Long-timescale molecular dynamics simulations of protein structure and function. Curr Opin Struct Biol 2009;19:120-7
15. Lin JH, Perryman AL, Schames JR, McCammon JA. Computational drug design accommodating receptor flexibility: the relaxed complex scheme. J Am Chem Soc 2002;124:5632-3
16. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996;274:1531-4
17. Sherman W, Day T, Jacobson MP, et al. Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 2006;49:534-54
18. Sherman W, Beard HS, Farid R. Use of an induced fit receptor structure in virtual screening. Chem Biol Drug Des 2006;67:83-4
19. Northrup SH, Erickson HP. Kinetics of protein-protein association explained by Brownian dynamics computer simulation. Proc Natl Acad Sci USA 1992;89:3338-42
20. Wade RC, Gabdoulline RR, Lüdemann SK, Lounnas V. Electrostatic steering and ionic tethering in enzyme-ligand binding: insights from simulations. Proc Natl Acad Sci USA 1998;95:5942-9
21. Veljkovic V. A theoretical approach to preselection of carcinogens and chemical carcinogenesis. Gordon & Breach; New York: 1980
22. Veljkovic V, Slavic I. Simple general-model pseudopotential. Phys Rev Lett 1972;29:105-7
23. Veljkovic V. The dependence of the Fermi energy on the atomic number. Phys Lett 1973;45A:41-2
24. Todeschini R, Consoni V. Molecular descriptors for chemoinformatics. Wiley VCH Verlag; Weinheim: 2009
25. Veljkovic V, Veljkovic N, Este JA, et al. Application of the EIIP/ISM bioinformatics concept in development of new drugs. Curr Med Chem 2007;14:441-53
26. Veljkovic N, Glisic S, Perovic V, Veljkovic V. The role of long-range intermolecular interactions in discovery of new drugs. Expert Opin Drug Discov 2011;6:1263-70
27. Bolton E, Wang Y, Thiessen PA, Bryant SH. PubChem: integrated platform of small molecules and biological activities. Chapter 12. In: Annual reports in computational chemistry. Volume 4 American Chemical Society; Washington DC:
28. Veljkovic N, Glisic S, Prljic J, et al. Simple and general criterion for "in silico" screening of candidate HIV drugs. Curr Pharm Biotechn 2012; Epub ahead of print CPB-EPUB-20120601-1
29. Veljkovic V, Mouscadet JF, Veljkovic N, et al. Simple criterion for selection of flavonoid compounds with anti-HIV activity. Bioorg Med Chem Lett 2007;17:1226-32
30. Tintori C, Manetti F, Veljkovic N, et al. Novel virtual screening protocol based on the combined use of molecular modeling and electron-ion interaction potential techniques to design HIV-1 integrase inhibitors. Chem Inf Model 2007;47:1536-44
31. Mugnaini C, Rajamaki S, Tintori C, et al. Toward novel HIV-1 integrase binding inhibitors: molecular modeling, synthesis, and biological studies. Bioorg Med Chem Lett 2007;17:5370-3
32. Division of AIDS Anti-HIV/OI/TB Therapeutics Database. National Institutes of Health, U.S. Department of Health and Human Services. Available from: http://chemdb.niaid.nih.gov/AboutChemDB.aspx
33. Spence RA, Kati WM, Anderson KS, Johnson KA. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995;267:988-93
34. Spence RA, Anderson KS, Johnson KA. HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors. Biochemistry 1996;35:1054-63
35. Maga G, Amacker M, Ruel N, et al. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. J Mol Biol 1997;274:738-47
36. Maga G, Spadari S. Combinations against combinations: associations of anti-HIV 1 reverse transcriptase drugs challenged by constellations of drug resistance mutations. Curr Drug Metab 2002;3:73-95
37. Basavapathruni A, Vingerhoets J, de Bethune MP, et al. Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations. Iochemistry 2006;45:7334-40
38. Xia Q, Radzio J, Anderson KS, Sluis-Cremer N. Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses. Protein Sci 2007;16:1728-37
39. Lin LP, Huang LS, Lin CW, et al. Determination of binding constant of DNA-binding drug to target DNA by surface plasmon resonance biosensor technology. Curr Drug Targets Immune Endocr Metabol Disord 2005;5:61-72
40. Besenicar M, Macek P, Lakey JH, Anderluh G. Surface plasmon resonance in protein-membrane interactions. Chem Phys Lipids 2006;141:169-78
41. Lausted C, Hu Z, Hood L, Campbell CT. SPR imaging for high throughput, label-free interaction analysis. Comb Chem High Throughput Screen 2009;12:741-51
42. Marshall GR. Limiting assumptions in structure-based design: binding entropy. J Comput Aided Mol Des 2012;26:3-8
43. Caporuscio F, Tafi A. Pharmacophore modelling: a forty year old approach and its modern synergies. Curr Med Chem 2011;18:2543-53
44. McCammon JA. Target flexibility in molecular recognition. Biochim Biophys Acta 2005;1754:221-4
45. Velazquez-Campoy A, Freire E. Incorporating target heterogeneity in drug design. J Cell Biochem Suppl 2001(Suppl 37):82-8
46. Velazquez-Campoy A, Muzammil S, Ohtaka H, et al. Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design. Curr Drug Targets Infect Disord 2003;3(4):311-28
47. Freyer MW, Lewis EA. Isothermal titration calorimetry: experimental design, data analysis, and probing macromolecule/ligand binding and kinetic interactions. Methods Cell Biol 2008;84:79-113
48. Liang Y. Applications of isothermal titration calorimetry in protein science. Acta Biochim Biophys Sin (Shanghai) 2008;40:565-76
49. Knox RS. Forster's resonance excitation transfer theory: not just a formula. J Biomed Opt 2012;17:011003
50. Lohse MJ, Hoffmann C, Nikolaev VO, et al. Kinetic analysis of G protein-coupled receptor signaling using fluorescence resonance energy transfer in living cells. Adv Protein Chem 2007;74:167-88
51. Grum-Tokars V, Ratia K, Begaye A, et al. Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery. Virus Res 2008;133:63-73
52. Tatham MH, Hay RT. FRET-based in vitro assays for the analysis of SUMO protease activities. Methods Mol Biol 2009;497:253-68
53. Degorce F, Card A, Soh S, et al. HTRF: a technology tailored for drug discovery-a review of theoretical aspects and recent applications. Curr Chem Genomics 2009;3:22-32
54. Mancini F, De Simone A, Andrisano V. Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in vitro methods for characterization of inhibitors. Anal Bioanal Chem 2011;400:1979-96
55. Smiley RD, Hammes GG. Single molecule studies of enzyme mechanisms. Chem Rev 2006;106:3080-94
56. Blank K, De Cremer G, Hofkens J. Fluorescence-based analysis of enzymes at the single-molecule level. Biotechnol J 2009;4:465-79
57. Rissin DM, Gorris HH, Walt DR. Distinct and long-lived activity states of single enzyme molecules. J Am Chem Soc 2008;130:5349-53
58. Gorris HH, Rissin DM, Walt DR. Stochastic inhibitor release and binding from single-enzyme molecules. Proc Natl Acad Sci USA 2007;104:17680-5
59. Wallrabe H, Periasamy A. Imaging protein molecules using FRET and FLIM microscopy. Curr Opin Biotechnol 2005;16:19-27
60. Sun Y, Wallrabe H, Seo SA, Periasamy A. FRET microscopy in 2010: the legacy of Theodor Forster on the 100th anniversary of his birth. ChemPhysChem 2010;12:462-74
61. Stepanenko OV, Verkhusha VV, Kuznetsova IM, et al. Fluorescent proteins as biomarkers and biosensors: throwing color lights on molecular and cellular processes. Curr Protein Pept Sci 2008;9:338-69
62. Stepanenko OV, Shcherbakova DM, Kuznetsova IM, et al. Modern fluorescent proteins: from chromophore formation to novel intracellular applications. Biotechniques 2011;51:313-14.316,318 passim
63. Kovarik ML, Allbritton NL. Measuring enzyme activity in single cells. Trends Biotechnol 2011;29:222-30
64. He M, Edgar JS, Jeffries GD, et al. Selective encapsulation of single cells and subcellular organelles into picoliter-and femtoliter-volume droplets. Anal Chem 2005;77:1539-44
65. Baret JC, Miller OJ, Taly V, et al. Fluorescence-activated droplet sorting (FADS): efficient microfluidic cell sorting based on enzymatic activity. Lab Chip 2009;9:1850-8
66. El-Ali J, Sorger PK, Jensen KF. Cells on chips. Nature 2006;442:403-11
67. Di Carlo D, Aghdam N, Lee LP. Single-cell enzyme concentrations, kinetics, and inhibition analysis using high-density hydrodynamic cell isolation arrays. Anal Chem 2006;78:4925-30
68. Di Carlo D, Wu LY, Lee LP. Dynamic single cell culture array. Lab Chip 2006;6:1445-9
69. Xue Q, Yeung ES. Variability of intracellular lactate dehydrogenase isoenzymes in single human erythrocytes. Anal Chem 1994;66:1175-8
70. Meredith GD, Sims CE, Soughayer JS, Allbritton NL. Measurement of kinase activation in single mammalian cells. Nat Biotechnol 2000;18:309-12
71. Jiang D, Sims CE, Allbritton NL. Single-cell analysis of phosphoinositide 3-kinase and phosphatase and tensin homolog activation. Faraday Discuss 2011;149:187-200.discussion 227-45
72. Krylov SN, Zhang Z, Chan NW, et al. Correlating cell cycle with metabolism in single cells: combination of image and metabolic cytometry. Cytometry 1999;37:14-20
73. Krylov SN, Arriaga EA, Chan NW, et al. Metabolic cytometry: monitoring oligosaccharide biosynthesis in single cells by capillary electrophoresis. Anal Biochem 2000;283:133-5
74. Radi M, Falchi F, Garbelli A, et al. Discovery of the first small molecule inhibitor of human DDX3 specifically designed to target the RNA binding site: towards the next generation HIV-1 inhibitors. Bioorg Med Chem Lett 2012;22:2094-8
75. Maga G, Falchi F, Garbelli A, et al. Pharmacophore modeling and molecular docking led to the discovery of inhibitors of human immunodeficiency virus-1 replication targeting the human cellular aspartic acid-glutamic acid-alanine-aspartic acid box polypeptide 3. J Med Chem 2008;5:6635-8
76. Radi M, Falciani C, Contemori L, et al. A multidisciplinary approach for the identification of novel HIV-1 nonnucleoside reverse transcriptase inhibitors: S-DABOCs and DAVPs. ChemMedChem 2008;3:573-93
77. Barreca ML, De Luca L, Iraci N, et al. Structure-based pharmacophore identification of new chemical scaffolds as non-nucleoside reverse transcriptase inhibitors. J Chem Inf Model 2007;47:557-62
78. Manetti F, Locatelli GA, Maga G, et al. A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem 2006;49:3278-86
79. Fattorusso C, Gemma S, Butini S, et al. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity. J Med Chem 2005;48:7153-65
80. Ingale KB, Bhatia MS. HIV-1 integrase inhibitors: a review of their chemical development. Antivir Chem Chemother 2011;22:95-105
81. Vangelista L, Secchi M, Lusso P. Rational design of novel HIV-1 entry inhibitors by RANTES engineering. Vaccine 2008;26:3008-15